Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections.

North Clin Istanb · 2024 · PMC11487320 · PMID 39431040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the maximum injection interval differences did not reach statistical significance in our study, the percentage of treatment interval of 4 weeks was higher in the IVR (28.6%) than in the IVA (13.2%) group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.